OBJECTIVE: This study investigated the potential use of serum follistatin (FST) as a marker for ovarian cancer alongside serum cancer antigen-125 (CA-125). METHODS: Serum samples were collected from patients with ovarian cancer (n = 45), benign ovarian cysts (n = 40) or other cancers (n = 100) and from healthy subjects (n = 60) for the determination of FST and CA-125 levels using enzyme-linked immunosorbent assays. Expression of FST in ovarian tissue was investigated using immunohistochemical staining. RESULTS: Compared with healthy subjects and patients with benign ovarian cysts, serum FST and CA-125 levels were significantly increased in patients with ovarian cancer. Using the 95% confidence interval for the healthy subjects group as the cut-off value, tumour marker sensitivity and specificity in ovarian cancer were 53.3% and 97% for FST and 77.8% and 84% for CA-125, respectively. Tissue expression of FST protein was more pronounced in ovarian cancer than in normal ovary. CONCLUSIONS: The serum FST level was elevated in the peripheral blood of patients with ovarian cancer and has potential as a tumour marker for ovarian cancer diagnosis. It may be particularly useful when combined with CA-125 detection to reduce the number of false-positive results.
OBJECTIVE: This study investigated the potential use of serum follistatin (FST) as a marker for ovarian cancer alongside serum cancer antigen-125 (CA-125). METHODS: Serum samples were collected from patients with ovarian cancer (n = 45), benign ovarian cysts (n = 40) or other cancers (n = 100) and from healthy subjects (n = 60) for the determination of FST and CA-125 levels using enzyme-linked immunosorbent assays. Expression of FST in ovarian tissue was investigated using immunohistochemical staining. RESULTS: Compared with healthy subjects and patients with benign ovarian cysts, serum FST and CA-125 levels were significantly increased in patients with ovarian cancer. Using the 95% confidence interval for the healthy subjects group as the cut-off value, tumour marker sensitivity and specificity in ovarian cancer were 53.3% and 97% for FST and 77.8% and 84% for CA-125, respectively. Tissue expression of FST protein was more pronounced in ovarian cancer than in normal ovary. CONCLUSIONS: The serum FST level was elevated in the peripheral blood of patients with ovarian cancer and has potential as a tumour marker for ovarian cancer diagnosis. It may be particularly useful when combined with CA-125 detection to reduce the number of false-positive results.
Authors: Grégoire F Le Bras; Holli A Loomans; Chase J Taylor; Frank L Revetta; Claudia D Andl Journal: Lab Invest Date: 2014-07-28 Impact factor: 5.662
Authors: Ji Hyun Kim; Denethia S Green; Young Min Ju; Mollie Harrison; J William Vaughan; Anthony Atala; Sang Jin Lee; John D Jackson; Cory Nykiforuk; James J Yoo Journal: Front Bioeng Biotechnol Date: 2022-07-22
Authors: Sonia Iyer; Shuang Zhang; Simge Yucel; Heiko Horn; Sean G Smith; Ferenc Reinhardt; Esmee Hoefsmit; Bimarzhan Assatova; Julia Casado; Marie-Charlotte Meinsohn; M Inmaculada Barrasa; George W Bell; Fernando Pérez-Villatoro; Kaisa Huhtinen; Johanna Hynninen; Jaana Oikkonen; Pamoda M Galhenage; Shailja Pathania; Paula T Hammond; Benjamin G Neel; Anniina Farkkila; David Pépin; Robert A Weinberg Journal: Cancer Discov Date: 2020-11-06 Impact factor: 39.397